Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma

Figure 1

Swimmer plot of patients receiving mogamulizumab combination therapy. This swimmer plot shows the duration of mogamulizumab combination therapy and outcomes for patients (n = 19) ranked by disease stage at initiation of mogamulizumab. Overlying bars depict the duration of mogamulizumab therapy and the duration of response for evaluable patients (n = 16). Time on mogamulizumab combination therapy is shown in gray. Time on mogamulizumab monotherapy, if occurred, is shown in black. The duration of a complete response to therapy, if occurred, is shown in green. The duration of a partial response to therapy, if occurred, is shown in blue. A red X represents the time point at which progressive disease (PD) and/or loss of response (LOR) occurred. Response to mogamulizumab, progression of disease, and loss of response is defined by the ISCL/USCLC/EORTC criteria [6]. Of note, patient 13 received pembrolizumab in between courses of mogamulizumab. Patient 14 progressed twice while receiving mogamulizumab; initial progression in the skin was treated by low-dose total skin electron beam therapy, resulting in temporary improvement followed by subsequent progression.